Candriam S.C.A. Bicycle Therapeutics PLC Transaction History
Candriam S.C.A.
- $15.6 Billion
- Q1 2025
A detailed history of Candriam S.C.A. transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Candriam S.C.A. holds 1,205,207 shares of BCYC stock, worth $10.2 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
1,205,207
Previous 1,087,876
10.79%
Holding current value
$10.2 Million
Previous $15.2 Million
32.82%
% of portfolio
0.07%
Previous 0.09%
Shares
12 transactions
Others Institutions Holding BCYC
# of Institutions
101Shares Held
42.8MCall Options Held
15.6KPut Options Held
27.7K-
Baker Bros. Advisors LP New York, NY10.9MShares$92.5 Million1.1% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.69MShares$31.4 Million0.08% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.45MShares$29.3 Million7.08% of portfolio
-
Armistice Capital, LLC New York, NY2.67MShares$22.7 Million0.35% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.66MShares$22.6 Million0.12% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $252M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...